Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1991 1
1992 1
1993 4
1994 4
1996 4
1997 10
1998 6
1999 5
2000 7
2001 8
2002 6
2003 3
2004 4
2005 7
2006 10
2007 23
2008 18
2009 23
2010 12
2011 13
2012 22
2013 31
2014 28
2015 32
2016 27
2017 34
2018 38
2019 26
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

350 results
Results by year
Filters applied: . Clear all
Page 1
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®.
Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ; EMPA-REG OUTCOME® Investigators. Kaku K, et al. Circ J. 2017 Jan 25;81(2):227-234. doi: 10.1253/circj.CJ-16-1148. Epub 2016 Dec 23. Circ J. 2017. PMID: 28025462 Free article. Clinical Trial.
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064 Clinical Trial.
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. Wiviott SD, et al. Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7. Am Heart J. 2018. PMID: 29898853 Clinical Trial.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Fitchett D, et al. Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511. Eur Heart J. 2018. PMID: 29020355 Clinical Trial.
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. Inzucchi SE, et al. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4. Diabetes Care. 2018. PMID: 29203583 Clinical Trial.
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study.
Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, Thompson MM, de Lusignan S, Ray KK, Hinchliffe RJ. Brownrigg JR, et al. Lancet Diabetes Endocrinol. 2016 Jul;4(7):588-97. doi: 10.1016/S2213-8587(16)30057-2. Epub 2016 May 20. Lancet Diabetes Endocrinol. 2016. PMID: 27216886 Free article.
350 results
Jump to page
Feedback